Desenkephalin-gamma-endorphin and neuroleptics counteract the DP-7-ATN-induced hypomotility after intra-accumbens treatment.
Injection of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin (DP-7-ATN, 1 fg to 1 microgram) into the nucleus accumbens decreased motor activity. The reduction of motor activity was reversed by pretreatment with haloperidol (10 pg), (-)-sulpiride (10 pg) or desenkephalin-gamma-endorphin (DE gamma E) (100 pg). These results support the hypothesis that DE gamma E may interfere with presynaptically located D-2 dopamine receptor systems in the nucleus accumbens. Furthermore, the use of DP-7-ATN in the described test procedure might be a useful model for testing novel neuroleptic compounds in vivo.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D007267:Injections; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009281:Naphthalenes / Q000037:antagonists & inhibitors*; D009714:Nucleus Accumbens; D051381:Rats; D011919:Rats, Inbred Strains; D013469:Sulpiride / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D001615:beta-Endorphin / Q000494:pharmacology*
D014150:Antipsychotic Agents; D009281:Naphthalenes; D013764:Tetrahydronaphthalenes; D001615:beta-Endorphin; C037253:2-(N,N-dipropyl)amino-6,7-dihydroxytetralin; C033558:des-enkephalin-gamma-endorphin; D013469:Sulpiride; D006220:Haloperidol